K. A. Mesquita

Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention.

A. Green, E. Rakha, V. Band, 2018, Cancer research.

Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors

K. A. Mesquita, S. Madhusudan, Adel Alblihy, 2019, Expert Review of Precision Medicine and Drug Development.

PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.

E. Rakha, R. Ali, I. Miligy, 2020, Cancer letters.

Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells

P. Oliveira, A. Branco, I. Vega-Naredo, 2014, Cell Death and Differentiation.

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers

David M. Wilson, A. Jadhav, E. Rakha, 2021, Cancers.

Mitochondria in cancer stem cells: a target for therapy.

P. Oliveira, I. Vega-Naredo, K. A. Mesquita, 2013, Recent patents on endocrine, metabolic & immune drug discovery.

ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

E. Rakha, M. Toss, K. A. Mesquita, 2019, Gynecologic oncology.

Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cells

Isabel S Sousa, P. Oliveira, I. Vega-Naredo, 2015, Oncotarget.

Mitochondrial biology in cancer stem cells.

P. Oliveira, I. Vega-Naredo, K. A. Mesquita, 2017, Seminars in cancer biology.

Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers

A. Tomkinson, E. Rakha, N. Mongan, 2021, Theranostics.